Dr. Stephen Goutman's lab at the University of Michigan focuses on understanding amyotrophic lateral sclerosis (ALS), a debilitating neurological condition, by investigating the role of the immune system and environmental exposures. The lab aims to develop diagnostic tools and therapeutic strategies based on immune signatures and occupational risks associated with ALS, utilizing advanced technologies like spectral flow cytometry to analyze immune profiles in patients. Their research seeks to enhance predictions of disease progression and inform prevention strategies for individuals at higher risk of developing ALS.

Dr. Brian Callaghan's lab focuses on understanding the effectiveness and cost-effectiveness of new treatments for Alzheimer's disease, especially in Black and low-income populations. By evaluating the real-world impacts of anti-amyloid medications, the lab aims to address healthcare disparities and improve access to effective treatments. This research is crucial for ensuring that vulnerable populations receive equitable healthcare benefits while navigating potential challenges like adverse events and cost barriers.

Dr. Mellanie V Springer’s lab focuses on understanding the cognitive challenges faced by stroke survivors, particularly the risk of Vascular Cognitive Impairment and Dementia (VCID). The team investigates how everyday activities like reading and solving puzzles can help protect brain health after a stroke. They also explore the impact of sleep disorders, such as obstructive sleep apnea, on cognitive decline in stroke patients. By identifying modifiable factors, the lab aims to develop practical interventions to improve cognitive outcomes for stroke survivors.

Dr. Catherine Cook Kaczorowski's research lab at the University of Michigan focuses on understanding the genetic factors that influence cognitive aging and Alzheimer's disease (AD). The team studies how genetic and environmental factors, including sleep and diet, impact brain function and resilience to cognitive decline. By using advanced mouse models and comparing findings to human datasets, the lab aims to identify potential therapeutic targets to improve quality of life for those affected by Alzheimer's disease and cognitive impairments.

Dr. Yu Wang's lab at the University of Michigan focuses on understanding epilepsy associated with mTORopathies, particularly in how these conditions develop and progress. They use advanced techniques to explore the cellular and molecular changes in the brain that lead to epilepsy, especially in children with drug-resistant forms of the disease. The lab combines animal models with human tissue studies to investigate potential therapeutic strategies and improve seizure outcomes.

Dr. Eva Feldman's lab at the University of Michigan focuses on understanding the mechanisms behind neurodegenerative diseases like ALS and the complications of diabetes, particularly peripheral neuropathy. The lab investigates how environmental factors and lifestyle choices impact nerve health and disease progression, aiming to develop targeted prevention and treatment strategies for these debilitating conditions.

Dr. Peter K Todd's lab at the University of Michigan focuses on understanding the genetic causes of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The lab investigates how a specific genetic mutation leads to the production of toxic proteins in neurons, potentially revealing new targets for therapeutic intervention. Their research combines cellular models, including patient-derived stem cells, to explore the mechanisms of disease and improve outcomes for affected individuals.

Dr. Sami Barmada's lab at the University of Michigan focuses on understanding the role of a specific protein called TDP43 in neurodegenerative diseases like ALS and frontotemporal dementia. They investigate how certain shortened forms of TDP43 accumulate in neurons and contribute to disease. By studying these proteins in human tissues and using advanced techniques, the lab aims to uncover the origins of TDP43-related diseases and explore potential new treatments.

Dr. Devin L Brown's lab at the University of Michigan focuses on understanding how sleep apnea affects stroke patients, particularly the differences in how it manifests among various ethnic groups. By investigating the underlying causes of sleep apnea after a stroke, the lab aims to create personalized treatment plans that improve patient outcomes. This research is crucial because stroke can severely disrupt brain function, leading to high rates of sleep apnea in affected individuals, which is often overlooked in traditional care.

Dr. Vikas Kotagal's lab focuses on understanding and reducing the risk of falls in individuals with Parkinson's disease, particularly those experiencing cognitive impairments. They are investigating the effects of a drug called varenicline, which may enhance attention and improve walking performance, potentially leading to fewer falls. The lab combines clinical research with advanced imaging techniques to explore how brain function is linked to movement problems in Parkinson's patients.

Dr. Henry L. Paulson's lab at the University of Michigan focuses on understanding the mechanisms behind age-related neurodegenerative diseases, especially how proteins involved in cellular quality control, such as ubiquitin, contribute to these disorders. The lab aims to discover new treatments by studying how these proteins become dysfunctional and lead to diseases like Alzheimer's and Huntington's. By investigating the complex biology of these proteins, the research seeks to identify potential therapeutic targets.